0001415889-22-000284.txt : 20220104
0001415889-22-000284.hdr.sgml : 20220104
20220104210102
ACCESSION NUMBER: 0001415889-22-000284
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220103
FILED AS OF DATE: 20220104
DATE AS OF CHANGE: 20220104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Litvack Frank
CENTRAL INDEX KEY: 0001310715
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34058
FILM NUMBER: 22508525
MAIL ADDRESS:
STREET 1: C/O CONOR MEDSYSTEMS, INC.
STREET 2: 1003 HAMILTON COURT
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CAPRICOR THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001133869
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8840 WILSHIRE BLVD
STREET 2: 2ND FLOOR
CITY: BEVERLY HILLS
STATE: CA
ZIP: 90211
BUSINESS PHONE: (310) 358-3200
MAIL ADDRESS:
STREET 1: 8840 WILSHIRE BLVD
STREET 2: 2ND FLOOR
CITY: BEVERLY HILLS
STATE: CA
ZIP: 90211
FORMER COMPANY:
FORMER CONFORMED NAME: Nile Therapeutics, Inc.
DATE OF NAME CHANGE: 20070920
FORMER COMPANY:
FORMER CONFORMED NAME: SMI PRODUCTS INC
DATE OF NAME CHANGE: 20010206
4
1
form4-01042022_090154.xml
X0306
4
2022-01-03
0001133869
CAPRICOR THERAPEUTICS, INC.
CAPR
0001310715
Litvack Frank
C/O CAPRICOR THERAPEUTICS, INC.
8840 WILSHIRE BLVD., 2ND FLOOR
BEVERLY HILLS
CA
90211
true
false
false
false
Common Stock
2022-01-03
4
M
0
154543
1.39
A
174934
D
Common Stock
2022-01-03
4
F
0
67552
3.18
D
107382
D
Stock Option (Right to Buy)
1.39
2022-01-03
4
M
0
154543
0
D
2022-04-27
Common Stock
154543
0
D
Stock Option (Right to Buy)
3.18
2022-01-03
4
A
0
252250
0
A
2032-01-03
Common Stock
252250
252250
D
Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on January 3, 2022 of $3.18. The options would otherwise expire on April 27, 2022, pursuant to their terms.
This option was granted on April 27, 2012 and was previously reported as covering 1,545,435 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
The shares vest 1/48th of the first day of each month, commencing February 1, 2022, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.
/s/ Linda Marban, Attorney-in-Fact
2022-01-04